Harbour BioMed (Guangzhou) Co. Ltd. — Biomedical Watch V2

Traitements5programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
HBM9161 Injection (340 mg)Primary Objectives: To investigate the efficacy of HBM9161 in patients with attack of MG in China	Myasthénie	Phase 2	À vérifier	China	À vérifier
HBM9161 Injection (680mg and 340 mg)Primary Objectives: To investigate the efficacy of HBM9161 in patients with attack of MG in China	Myasthénie	Phase 2	À vérifier	China	À vérifier
HBM9161 Injection (680mg)The primary study objective is to evaluate medium- and long-term safety of HBM9161 in combination with background treatment for gMG patients through the observation on adverse events and laboratory abnormalities during study period.	Myasthénie	Phase 3	À vérifier	China	À vérifier
HBM9161 Injection (680mg and 340 mg)Primary Objectives: To investigate the efficacy of HBM9161 in patients with attack of MG in China	Myasthénie	Phase 2	À vérifier	China	À vérifier
HBM9161 Injection (680mg)The primary study objective is to evaluate medium- and long-term safety of HBM9161 in combination with background treatment for gMG patients through the observation on adverse events and laboratory abnormalities during study period.	Myasthénie	Phase 3	À vérifier	China	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
HBM9161 Injection (680mg)	Myasthénie	Phase 3	NCT05332210	Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis	COMPLETED
HBM9161 Injection (680mg and 340 mg)	Myasthénie	Phase 2	NCT04346888	A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients	COMPLETED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.